Group 1 - The company Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for "Shengxian Decoction Granules" from the National Medical Products Administration [1] - The function and indications of Shengxian Decoction Granules include tonifying Qi and lifting the sinking, used for the syndrome of Qi sinking, characterized by symptoms such as shortness of breath, difficulty in breathing, and weak pulse [1]

Group 1 - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for "Shengxian Decoction Granules" from the National Medical Products Administration [1] - The function and indications of Shengxian Decoction Granules include tonifying Qi and lifting the sinking of Qi, used for symptoms of Qi deficiency with manifestations such as shortness of breath, difficulty in breathing, and weak pulse [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for "Shengxian Decoction Granules" from the National Medical Products Administration [1] Group 1 - The "Shengxian Decoction Granules" are indicated for the treatment of Qi deficiency syndrome, characterized by symptoms such as shortness of breath, difficulty in breathing, and weak pulse [1] - The product is specifically used for conditions related to "Qi sinking" [1]

每经头条（nbdtoutiao）——5万亿ETF的370名基金经理薪酬大揭秘！他们的日常工作，就是跟着指数 买股票吗？ （记者 张明双） 2025年1至6月份，吉林敖东的营业收入构成为：医药行业占比73.63%，连锁药店批发和零售占比 16.59%，食品占比7.39%，其他行业占比1.76%，其他业务占比0.62%。 截至发稿，吉林敖东市值为225亿元。 每经AI快讯，吉林敖东（SZ 000623，收盘价：18.82元）9月19日晚间发布公告称，近日，吉林敖东药 业集团股份有限公司控股子公司吉林敖东洮南药业股份有限公司收到国家药品监督管理局下发的"升陷 汤颗粒"的《药品注册证书》。产品名称为"升陷汤颗粒"。 ...